Mydecine Innovations Group™ (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology company developing innovative first- and second-generation novel therapeutics to treat unmet needs in mental health and addiction disorders. Focusing on psychedelic compounds and other novel molecules with therapeutic potential, the Mydecine business model combines their world-class team and drug development infrastructure with advanced technology, clinical trials and data outcomes. Founded in 2020 to address a significant lack of innovation in the mental health treatment environment, Mydecine currently is pursuing indications such as addiction, PTSD and anxiety. By collaborating with some of the world’s foremost authorities, the company aims to responsibly fast track the development of novel medicines to provide patients with safer and more effective treatment options. Mydecine’s leadership team combines vast experience in drug development, medicinal chemistry, clinical trials, and mental health and addiction disorders. Supported by a top-notch medical and scientific advisory board of global experts, the company is progressing a robust R&D pipeline of psychedelic-derived therapeutics, novel compounds and controlled drug delivery systems.
RkJQdWJsaXNoZXIy NDMyMDk=